Recombinant adenovirus carrying the hepatocyte nuclear factor-1alpha gene inhibits hepatocellular carcinoma xenograft growth in mice

Hepatology

Volumn 54, Issue 6, 2011, Pages 2036-2047

  Zeng, Xin ^a   Lin, Yong ^a   Yin, Chuan ^a   Zhang, Xin ^b   Ning, Bei Fang ^a   Zhang, Qing ^a   Zhang, Jun Ping ^c   Qiu, Lei ^c   Qin, Xiao Ran ^d   Chen, Yue Xiang ^a   Xie, Wei Fen ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b CHINESE NATIONAL HUMAN GENOME CENTER AT SHANGHAI   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

^d ChemPartner   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; EPITHELIAL CELL ADHESION MOLECULE; GENE THERAPY AGENT; HEPATOCYTE NUCLEAR FACTOR 1ALPHA; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN P21; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GENE THERAPY; CARCINOGENICITY; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL DIFFERENTIATION; CELL PROLIFERATION; CHEMOSENSITIVITY; CLONOGENESIS; FIBROBLAST; GENE CONSTRUCT; GENE EXPRESSION; GENETIC TRANSFECTION; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOLOGY; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR ASSOCIATED FIBROBLAST; TUMOR XENOGRAFT; VIRUS RECOMBINANT;

ADENOVIRIDAE; ANIMALS; ANTIGENS, CD; ANTIGENS, NEOPLASM; CARCINOMA, HEPATOCELLULAR; CELL ADHESION MOLECULES; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; GLYCOPROTEINS; HEPATOCYTE NUCLEAR FACTOR 1-ALPHA; HUMANS; LIVER NEOPLASMS; MALE; MICE; MICRORNAS; NEOPLASM TRANSPLANTATION; P21-ACTIVATED KINASES; PEPTIDES; TRANSPLANTATION, HETEROLOGOUS;

EID: 82455171648     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.24647     Document Type: Article

References (36)

1. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006; 24: 2137-2150.
2. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907-9717.
3. Costa RH, Kalinichenko VV, Holterman AX, Wang X. Transcription factors in liver development, differentiation, and regeneration. HEPATOLOGY 2003; 38: 1331-1347.
4. Li J, Ning G, Duncan SA. Mammalian hepatocyte differentiation requires the transcription factor HNF-4α. Genes Dev 2000; 14: 464-474.
5. Kaestner KH, Hiemisch H, Schütz G. Targeted disruption of the gene encoding hepatocyte nuclear factor 3γ results in reduced transcription of hepatocyte-specific genes. Mol Cell Biol 1998; 18: 4245-4251.
6. Odom DT, Zizlsperger N, Gordon DB, Bell GW, Rinaldi NJ, Murray HL, et al. Control of pancreas and liver gene expression by HNF transcription factors. Science 2004; 303: 1378-1381.
7. Ishiyama T, Kano J, Minami Y, Iijima T, Morishita Y, Noguchi M. Expression of HNFs and C/EBPα is correlated with immunocytochemical differentiation of cell lines derived from human hepatocellular carcinomas, hepatoblastomas, and immortalized hepatocytes. Cancer Sci 2003; 94: 757-763.
8. Lazarevich NL, Cheremnova OA, Varga EV, Ovchinnikov DA, Kudrjavtseva EI, Morozova OV, et al. Progression of HCC in mice is associated with a downregulation in the expression of hepatocyte nuclear factors. HEPATOLOGY 2004; 39: 1038-1047.
9. Yin C, Lin Y, Zhang X, Chen YX, Zeng X, Yue HY, et al. Differentiation therapy of hepatocellular carcinoma in mice with recombinant adenovirus carrying hepatocyte nuclear factor-4alpha gene. HEPATOLOGY 2008; 48: 1528-1539.
10. Yue HY, Yin C, Hou JL, Zeng X, Chen YX, Zhong W, et al. Hepatocyte nuclear factor 4α attenuates hepatic fibrosis in rats through inhibiting epithelial-mesenchymal transition. Gut 2010; 59: 236-246.
11. Ning BF, Ding J, Yin C, Zhong W, Wu K, Zeng X, et al. Hepatocyte nuclear factor 4 alpha suppresses the development of hepatocellular carcinoma. Cancer Res 2010; 70: 7640-7651.
12. Lazarevich NL, Fleishman DI. Tissue-specific transcription factors in progression of epithelial tumors. Biochemistry (Mosc) 2008; 73: 573-591.
13. Pontoglio M, Barra J, Hadchouel M, Doyen A, Kress C, Bach JP, et al. Hepatocyte nuclear factor 1 inactivation results in hepatic dysfunction, phenylketonuria, and renal Fanconi syndrome. Cell 1996; 84: 575-585.
14. Pontoglio M, Sreenan S, Roe M, Pugh W, Ostrega D, Doyen A, et al. Defective insulin secretion in hepatocyte nuclear factor 1alpha-deficient mice. J Clin Invest 1998; 101: 2215-2222.
15. Kalkuhl A, Kaestner K, Buchmann A, Schwarz M. Expression of hepatocyte-enriched nuclear transcription factors in mouse liver tumours. Carcinogenesis 1996; 17: 609-612.
16. Ninomiya T, Hayashi Y, Saijoh K, Ohta K, Yoon S, Nakabayashi H, et al. Expression ratio of hepatocyte nuclear factor-1 to variant hepatocyte nuclear factor-1 in differentiation of hepatocellular carcinoma and hepatoblastoma. J Hepatol 1996; 25: 445-453.
17. Jeannot E, Poussin K, Chiche L, Bacq Y, Sturm N, Scoazec JY, et al. Association of CYP1B1 germ line mutations with hepatocyte nuclear factor 1alpha-mutated hepatocellular adenoma. Cancer Res 2007; 67: 2611-2616.
18. Bluteau O, Jeannot E, Bioulac-Sage P, Marqués JM, Blanc JF, Bui H, et al. Bi-allelic inactivation of TCF1 in hepatic adenomas. Nat Genet 2002; 32: 312-315.
19. Hellerbrand C, Amann T, Schlegel J, Wild P, Bataille F, Spruss T, et al. The novel gene MIA2 acts as a tumour suppressor in hepatocellular carcinoma. Gut 2008; 57: 243-251.
20. Pelletier L, Rebouissou S, Paris A, Rathahao-Paris E, Perdu E, Bioulac-Sage P, et al. Loss of hepatocyte nuclear factor 1alpha function in human hepatocellular adenomas leads to aberrant activation of signaling pathways involved in tumorigenesis. HEPATOLOGY 2010; 51: 557-566.
21. Braun CJ, Zhang X, Savelyeva I, Wolff S, Moll UM, Schepeler T, et al. p53-responsive microRNAs 192 and 215 are capable of inducing cell cycle arrest. Cancer Res 2008; 68: 10094-10104.
22. Hino K, Tsuchiya K, Fukao T, Kiga K, Okamoto R, Kanai T, et al. Inducible expression of microRNA-194 is regulated by HNF-1alpha during intestinal epithelial cell differentiation. RNA 2008; 14: 1433-1442.
23. Swenson ES, Guest I, Ilic Z, Mazzeo-Helgevold M, Lizardi P, Hardiman C, et al. Hepatocyte nuclear factor-1 as marker of epithelial phenotype reveals marrow-derived hepatocytes, but not duct cells, after liver injury in mice. Stem Cells 2008; 26: 1768-1777.
24. Xu L, Hui L, Wang S, Gong J, Jin Y, Wang Y, et al. Expression profiling suggested a regulatory role of liver-enriched transcription factors in human hepatocellular carcinoma. Cancer Res 2001; 61: 3176-3181.
25. Lapenna S, Giordano A. Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov 2009; 8: 547-566.
26. Smits VA, Klompmaker R, Vallenius T, Rijksen G, Mäkela TP, Medema RH. p21 inhibits Thr161 phosphorylation of Cdc2 to enforce the G2 DNA damage checkpoint. J Biol Chem 2000; 275: 30638-30643.
27. Guadagno TM, Newport JW. Cdk2 kinase is required for entry into mitosis as a positive regulator of Cdc2-cyclin B kinase activity. Cell 1996; 84: 73-82.
28. Li R, Waga S, Hannon GJ, Beach D, Stillman B. Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair. Nature 1994; 371: 534-537.
29. Cayrol C, Knibiehler M, Ducommun B. p21 binding to PCNA causes G1 and G2 cell cycle arrest in p53-deficient cells. Oncogene 1998; 16: 311-320.
30. Yang J, Zhou F, Xu T, Deng H, Ge YY, Zhang C, et al. Analysis of sequence variations in 59 microRNAs in hepatocellular carcinomas. Mutat Res 2008; 638: 205-209.
31. Meng Z, Fu X, Chen X, Zeng S, Tian Y, Jove R, et al. miR-194 is a marker of hepatic epithelial cells and suppresses metastasis of liver cancer cells in mice. HEPATOLOGY 2010; 52: 2148-2157.
32. Sell S. Stem cell origin of cancer and differentiation therapy. Crit Rev Oncol Hematol 2004; 51: 1-28.
33. Huang ME, Ye YC, Chen SR, Chai JR, Lu JX, Zhoa L, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988; 72: 567-572.
34. Yin C, Xie WF. Differentiation therapy with transcription factors might present as an ideal strategy for the treatment of cancer. HEPATOLOGY 2009; 50: 2046-2047.
35. Mazzocca A, Fransvea E, Dituri F, Lupo L, Antonaci S, Giannelli G. Down-regulation of connective tissue growth factor by inhibition of transforming growth factor beta blocks the tumor-stroma cross-talk and tumor progression in hepatocellular carcinoma. HEPATOLOGY 2010; 51: 523-534.
36. Banerjee A, Lang JY, Hung MC, Sengupta K, Banerjee SK, Baksi K, et al. Unfolded protein response is required in nu/nu mice microvasculature for treating breast tumor with tunicamycin. J Biol Chem 2011; 286: 29127-29138.